Introduction
============

Prosthetic joint infection (PJI) involves the joint prosthesis and contiguous tissue and is one of the main reasons for total arthroplasty failure [@B1], [@B2]. A wide range of microorganisms may cause PJI, most often Gram-positive bacteria, especially staphylococcal species, and Gram-negative pathogens [@B3]. However, other microorganisms can also be responsible for PJI, including fungi, particularly *Candida* species. PJI due to *Candida* is rare and represents a therapeutic challenge because no specific guidelines have been already established and published case reports vary widely in therapeutic approach [@B4]. Currently, the *gold standard*for treatment consists in a two-stage revision surgery [@B4], [@B5], although it is doubtful whether multiple procedures are able to provide any improvements and it is also unknown if other techniques such as one-stage exchange may be successful.

Here, we describe one patient seen at the Orthopaedics and Trauma Department of the Hospital Universitario Virgen de las Nieves (Granada, Spain) with PJI due to *C. albicans*which is being treated with antifungal drugs alone. Moreover, we have reviewed the medical literature searching case reports with *Candida*PJI discussing about the treatment methods applied.

Case Report
===========

A 66-year-old man had a right knee arthroplasty due to osteoarthritis suffered for several years. In January 2015, the patient underwent a two-stage right knee arthroplasty for septic arthritis due to *S. epidermidis,*as well as treatment with vancomycin + gentamycin. He was immunocompromised due to a splenectomy performed several years ago. In July 2016, the patient was attended at the Emergency Department of our Hospital due to pain, inflammation and joint leak for two weeks. The physical examination revealed inflammatory signs and swelling on the knee. The complete blood count, chemical profile and urinalysis were normal, except for a C-reactive protein (CRP) of 100 mg/L. A joint fluid (JF) was drawn by puncture from the affected knee and sent to the microbiology laboratory. The sample was inoculated after centrifugation in aerobic and anaerobic blood agar (BD Columbia Agar 5% Sheepblood^®^, Becton Dickinson), chocolate agar (BD Choco Agar, Becton Dickinson) and thioglycollate broth (BD^TM^ Fluid Thioglycollate Medium), all incubated at 37º C. Previously, 1 mL of the JF was inoculated into an aerobic blood culture bottle (BACTEC, 9240 BD, Becton Dickinson, Franklin Lakes, NJ, USA), being positive after 24 hours of incubation. Pathogen growth was observed on aerobic blood agar and chocolate agar. Identification of *C. albicans*and susceptibility to this strain were then tested using the Vitek system (BioMérieux, Mercy L\'Etoile, France) as well as mass spectrometry (Bruker Biotyper, Billerica, MA, USA). The isolate was susceptible to anidulafungin (0.015 µg/ml), micafungin (\<0.008 µg/ml) caspofungin (0.06 µg/ml), voriconazole (\<0.008 µg/ml), itraconazole (0,03 µg/ml) fluconazole (0,125 µg/ml), and amphotericin B (1 µg/ml). Breakpoints from CLSI were used for the majority of antifungal drugs, but only from EUCAST for amphotericin B [@B6], [@B7]. No blood cultures were taken at this stage. The patient rejected a prosthesis exchange, so a surgical procedure was then done with local debridement of the lesion, and five intraoperative periprosthetic tissue samples were taken from different locations, following recommendations of Kamme and Lindberg [@B8]. In the laboratory, each sample (1 cm^2^) was placed in 3 ml of sterile saline solution and vortexed for 30 seconds. Then, the sample was inoculated in aerobic and anaerobic blood agar (BD Columbia Agar 5% Sheepblood^®^, Becton Dickinson), chocolate agar (BD Choco Agar, Becton Dickinson) and thioglycolate broth (BD^TM^ Fluid Thioglycollate Medium, Becton Dickinson), all incubated at 37º C., and chromogenic candida agar (CandiSelect ^TM^, Bio-Rad, Redmond, WA, USA) incubated at 30º C. After 18 hours of incubation, microorganism growth was again observed and further identified as *C. albicans.*

Treatment with caspofungin (50 mg/day) was administered for 14 days, and the patient was then discharged under oral suppressive treatment with fluconazole (200 mg/12 h.) for 6 months. At 2 months of follow-up, the patient remained clinically stable, and laboratory findings were normal. At the moment, the patient has rejected prosthesis reimplantation and is currently waiting for a 6 months of antifungal treatment.

Literature Review
=================

We describe one patient recently seen at the Orthopaedics and Trauma Department of the Hospital Universitario Virgen de las Nieves (Granada, Spain) with PJI due to *C. albicans*.

Using the key words "fungal prosthetic joint infection" and "candida prosthetic joint infection" we searched MEDLINE (National Library of Medicine, Bethesda, MD), Web of Science, CINAHL, and Cochrane systematic review databases for case reports of this condition. We also checked the references cited in the papers for additional case reports published before 1966.

We traced 75 cases caused by *Candida* species and described in sufficient detail. These cases, along with our patient, are the basis of the present report. Among others, data on treatment, outcome and follow-up were recorded. A patient was considered to have *Candida* infection and was then included when a positive preoperative aspiration culture and/or a positive intraoperative culture were obtained. We did not include cases with *Candida* infection accompanied by another pathogen or cases with insufficient details for comparisons (clinical and laboratory data).

The basis for this review was recently published [@B9], but we have added three new cases of *Candida* PJI. Table [1](#T1){ref-type="table"} summarizes the treatment, outcome and follow-up of all cases here reviewed.

General Characteristics
-----------------------

There were 40 (52.6%) women, while the sex was not reported in two patients. The mean age of patients was 65.7 (± SD 18) yrs (range 35-93 yrs). Thirty-five cases were from the USA [@B10]-[@B33], 10 from Taiwan [@B34]-[@B36], six from the United Kingdom [@B37]-[@B41], six from Germany [@B42], four from France [@B43]-[@B45], three from Italy [@B46]-[@B48], two each from Japan [@B49], [@B50] and Spain \[9, and present report\], and one each from China [@B51], India [@B52], Slovenia [@B53], Belgium [@B54], Turkey [@B55], Canada [@B56], Malaysia [@B57] and Sweden [@B58]. No risk factors for candidal infection were found in 25 patients (32.8%). The joint involved was the knee in 38 (50%), the hip in 36 (47.3%) and the shoulder in two cases. Pain was reported by 44 (57.8%) patients, and the second most frequent symptom was swelling in 24 (31.5%) patients. Symptoms were not reported for 18 (23.6%) patients.

The most frequently isolated *Candida* species was *C. albicans*, found in 36 (47.3%), followed by *C. parapsilosis* in 17 (22.3%), *C. glabrata* in 12 (15.7%) and *C. tropicalis* in 8 (10.5%), with infection by both *C. albicans*and *C. glabrata* in one patient [@B40]. *Candida*species were diagnosed by culture of joint fluid (JF) aspirate in 33 cases (43.4%), culture of intraoperative sample (IoS) in 18 (23.6%) and culture of both JF and IoS samples in 19 (25%). Blood cultures were taken only in eight (10.5%) patients, and were positive for *Candida*in four of these (50%).

Antifungal treatment
--------------------

Seventy-five (98.6%) patients underwent antifungal treatment, with a single drug in 46 cases (60.5%), with two drugs in 16 cases (21%) and more than two in 13 (17.1%). Twenty-nine of the patients with monotherapy (63%) were treated with fluconazole and 14 (30.4%) with amphotericin B. One patient treated with amphotericin B alone suffered recurrence of the infection [@B33], while another patient treated with fluconazole alone died as a consequence of the infection [@B34].

Application of antifungal spacer cement was applied in ten (13.1%) patients (seven with amphotericin B and three with fluconazole).

Surgical treatment
------------------

Surgery was performed in 65 (85.5%) patients, 30 of whom (39.4%) underwent two-stage exchange arthroplasty; resection of arthroplasty without reimplantation was undertaken in other 30 (39.4%). One-stage exchange arthroplasty was undergone in 3 (3.9%) patients, and other procedures in two patients. Surgical treatment was not reported in 11 (14.4%) patients.

Outcome
-------

The final outcome was not reported in four patients. A favourable outcome was found in 58 (76.3%) patients after antifungal plus surgical treatment, in 11 (14.4%) after antifungal treatment alone and in one after surgery alone. A patient experienced recurrence of infection with fluconazole therapy, but his outcome was positive with miconazole plus drainage of fluid abscess [@B46].

Regarding to the type of surgery, all patients who underwent a two-stage exchange arthroplasty cured, although two of them suffered a bacterial infection [@B24], [@B57]. From the patients treated with resection arthroplasty, one dead after fluconazole treatment [@B34], two suffered amputation [@B14], [@B23] and two were found to have a bacterial infection [@B26], [@B56]. All three patients treated with one-stage exchange arthroplasty cured [@B40], [@B45]. Our two patients are currently well with antifungal treatment only, and no relapse of disease has been observed in the short follow-up.

Discussion
==========

PJI caused by *Candida* species is still a rare disease. However, the incidence is expected to rise because of the increasing number of patients implanted worldwide with joint arthroplasties [@B59], [@B60].

Risk factors for candidal infection, including immunosuppression, systemic disease and/or long-term antibiotics use, may play an essential role in the development of invasive candidal infections although other factors could be involved in triggering the infection, specially the presence of biofilm on bioprosthetic surfaces. Biofilm formation is considered the most prevalent growth form of microorganisms [@B61] and plays a key role in the development of clinical infections [@B62]. The majority of *C. albicans* infections are associated with biofilm formation on the host or on the surfaces of medical devices or prostheses [@B63]. Other factors, such as the adherence of *C. albicans* and their hydrolytic enzyme secretion may also have a strong influence on the development of PJI [@B64], and their modification may serve as possible targets for antifungal drugs against these infections.

Pain and swelling are the main symptoms of PJI due to *Candida* species, although the onset of symptoms can be insidious and development of the disease can be slow. Because symptoms are mild and there is frequently no diagnostic suspicion of PJI caused by *Candida*, the diagnosis can often be delayed. Another important problem is to elucidate whether the presence of *Candida* species in samples can be considered as a contaminant or not, because there is still no standard definition of PJI.

The treatment of choice for PJI caused by *Candida* species has not yet been established. The use of antifungal agents locally (mixed with cement) or systemically administered is a challenging issue. Locally, amphotericin B appears to be the ideal drug, but some studies have reported several problems [@B65], [@B66], while there is no report on the use of novel antifungal drugs. However, this option has not been usually used, because from 76 cases reviewed, antifungal spacers were applied in only 10 (the majority of them with amphotericin B). In all cases the outcome was positive, but curiously in two patients with resection arthroplasty plus amphotericin B impregnated cement spacer application, an amputation [@B14] and a bacterial infection [@B56] was observed.

For systemic administration, lipid formulations of amphotericin B and fluconazole are the drugs of choice for this type of infection, and echinocandins may be an option [@B67].

Various authors have analysed the activity of some antifungal drugs against *Candida* biofilms. Two reports described resistance to fluconazole in these structures [@B68], [@B69], while another study found that it interfered with the development of *C. albicans* biofilms [@B70]. On the other hand, lipid formulations of amphotericin B have shown activity against *C. albicans* biofilms [@B70]. Anidulafungin was more active than amphotericin B against *C. albicans* biofilms of 24-h maturation, but amphotericin B was more active than anidulafungin against *C. albicans* biofilms of 48-h maturation [@B71].

In this review, various types of antifungal drugs have been used for treatment, and the majority of them with a positive result. In table [1](#T1){ref-type="table"}, it can see that eleven patients (14.4%) were treated only with antifungal drugs \[9, 11, 17-19, 44, 49, 50, 51, 54, and present report\]; all these patients obtained a positive outcome, although the follow-up range from 3 to 72 months. According to these results, a correct and long treatment with antifungal drugs may be a good option, but due to the heterogeneity of the studies further research is required on this important issue, although it is highly recommended that these patients should be treated with drugs selected after antifungal susceptibility tests. In addition, a longer follow-up of these patients should be performed.

A two-stage arthroplasty exchange is currently considered the best approach in terms of eradication of the infection and preservation of the joint function in PJI caused by *Candida* species [@B4], [@B5]. Furthermore, when infection is chronic, this type of surgery is generally also recommended [@B72]. However, the success rate of this technique is controversial. One study reported a success rate of 93% for short-term infection control with 6 months of oral antifungal drugs after reimplantation [@B73], while another found that two-thirds of patients with PJ resection for fungal infection underwent reimplantation and that the infection was abolished in less than half of them [@B4].

On the other hand, resection arthroplasty was performed in around half of patients here reviewed (n=30). From these patients, in five of them the outcome was not initially favourable, and in three of them the final outcome was not reported. These results indicate that this procedure should not be the initial approach, also due to the important joint functional loss.

Regarding the third surgical method, some years ago Selmon et al reported a case with a positive outcome after a one-stage exchange arthroplasty [@B40]. Moreover, some authors have recently reported favourable outcome after one-stage exchange in selected cases of fungal PJI [@B45], [@B74]. In these cases, the responsible microorganism was identified post-operatively, with delayed specific antifungal treatment. In spite of this fact, the scientific evidence about these cases suggests that this technique may be appropriate in terms of eradication of infection, although the number of cases is still scarce. Further research should be done in order to establish the possible indications of one-stage exchange arthroplasty in cases of *Candida* PJI.

In summary, PJIs caused by *Candida*species are rare but fastidious infections that require a high index of suspicion because of their mild symptoms and insidious evolution. The diagnosis must be confirmed microbiologically and antifungal susceptibility testing of *Candida* strains is also highly recommended. The treatment is still not clearly defined and, although the association of long-term antifungal use with two-stage exchange arthroplasty is currently the gold standard to eradicate the infection, the analysis of the data of this review suggests the possibility of using one-stage exchange arthroplasty or antifungal treatment alone in order to obtain a favourable outcome for these patients. The next challenge for the scientific community is to establish the adequate algorithm for treatment in fungal PJI.

Informed consent
================

The patient described in this case report gave her informed consent for the inclusion in this publication.

###### 

Treatment, outcome and follow-up of 76 patients with *Candida* species PJI.

  ---------------------------------------------------------------------------------------------------------------------------------------
  Reference/\           Treatment\                                            Outcome                 Follow-up (months)            
  author                Antifungal treatment Surgical treatment                                                                     
  --------------------- ----------------------------------------------------- ----------------------- ----------------------------- -----
  51/Zhu Y              Amphotericin B\                                       NR                      Cure                          3
                        Voriconazole                                                                                                

  52/Reddy KJ           Fluconazole\                                          TEA                     Cure                          24
                        Amphotericin B ICS                                                                                          

  46/Artiaco S          Fluconazole\                                          Drainage of abscess     Cure                          12
                        Miconazole                                                                                                  

  37/Lidder S           Amphotericin B                                        TEA                     Cure                          24

  34/Ueng SWN           Fluconazole\                                          TEA                     Cure                          NR
                        Amphotericin B ICS                                                                                          

  34/Ueng SWN           Fluconazole                                           TEA                     Cure                          NR

  34/Ueng SWN           Fluconazole                                           TEA                     Cure                          NR

  34/Ueng SWN           Fluconazole\                                          TEA                     Cure                          NR
                        Amphotericin B ICS                                                                                          

  34/Ueng SWN           Fluconazole\                                          TEA                     Cure                          NR
                        Amphotericin B ICS                                                                                          

  34/Ueng SWN           Fluconazole                                           RA                      NR                            NR

  34/Ueng SWN           Fluconazole                                           RA                      NR                            NR

  34/Ueng SWN           Fluconazole                                           RA                      Dead                          NR

  42/Anagnostakos K     Caspofungin                                           TEA                     Cure                          28

  42/Anagnostakos K     Fluconazole                                           TEA                     Cure                          22

  42/Anagnostakos K     Fluconazole                                           TEA                     Cure                          70

  42/Anagnostakos K     Fluconazole                                           TEA                     Cure                          15

  42/Anagnostakos K     Fluconazole                                           TEA                     Cure                          36

  42/Anagnostakos K     Fluconazole                                           TEA                     Cure                          47

  47/Bartalesi F        Voriconazole\                                         TEA                     Cure                          48
                        Caspofungin + amphotericin B\                                                                               
                        Amphotericin B                                                                                              

  35/Wu MH              Fluconazole\                                          RA                      Cure                          12
                        Amphotericin B ICS                                                                                          

  11/ Kelesidis T       Fluconazole                                           NR                      Cure                          12

  12/Graw B             Fluconazole                                           TEA                     Cure\                         240
                                                                                                      Dead (UD)                     

  13/Bland CM           Liposomal amphotericin B + micafungin + fluconazole   RA                      NR                            NR

  43/Dumaine V          Caspofungin + flucytosine\                            RA\                     Cure                          15
                        Fluconazole + flucytosine                             Arthrodesis                                           

  53/Lejko-Zupanc T     Liposomal amphotericin B + fluconazole\               RA                      Cure                          36
                        Caspofungin                                                                                                 

  54/Fabry K            Voriconazole (3 days)\                                NR                      Cure\                         24
                        Oral voriconazole (7 months)                                                  Dead (UD)                     

  27 (/2004) Gaston G   Voriconazole\                                         RA                      Amputation                    6
                        Amphotericin B\                                                                                             
                        Amphotericin B ICS                                                                                          

  48/Lazzarini L        Amphotericin B                                        RA                      Cure                          48

  15/Wyman J            Fluconazole\                                          TEA                     Cure                          36
                        Amphotericin B                                                                                              

  16/Phelan DM          Amphotericin B\                                       TEA                     Cure                          73
                        Ketoconazole\                                                                                               
                        Fluconazole                                                                                                 

  16/Phelan DM          NR                                                    TEA                     Cure                          51

  16/Phelan DM          Amphotericin B\                                       TEA                     Cure                          70
                        Fluconazole                                                                                                 

  16/Phelan DM          Fluconazole\                                          TEA                     Cure                          17
                        Fluconazole ICS                                                                                             

  55/Açkgöz CZ          Fluconazole                                           RA\                     Cure                          7.5
                                                                              Arthrodesis                                           

  38/Bruce ASW          Fluconazole\                                          TEA                     Cure                          84
                        Fluconazole IB                                                                                              

  38/Bruce ASW          Fluconazole\                                          TEA                     Cure\                         48
                        Fluconazole IB                                                                Dead (UD)                     

  56/Marra F            Fluconazole\                                          RA (twice)              *E. coli* infection\          NR
                        Amphotericin B ICS                                                            NR final outcome              

  44/Merrer J           Fluconazole                                           NR                      Cure\                         11
                                                                                                      Dead (UD)                     

  36/Yang SH            Fluconazole                                           TEA                     Cure                          48

  39/Ramamohan N        Amphotericin B + 5-flucytosine                        TEA                     Cure                          24

  57/Badrul B           Fluconazole                                           TEA                     MRSA infection\               60
                                                                                                      Cure                          

  49/Wada M             Fluconazole                                           NR                      Cure                          36

  17/Brooks DH          Amphotericin B\                                       NR                      Cure                          24
                        Fluconazole                                                                                                 

  40/Selmon GPF         Amphotericin B\                                       OEA                     Cure                          48
                        Itraconazole + fluconazole                                                                                  

  18/Simonian PT        Ketoconazole                                          NR                      Cure                          72

  50/Fukasawa N         Fluconazole                                           NR                      *P. aeruginosa*\              24
                                                                                                      infection\                    
                                                                                                      Cure                          

  19/Cushing RD         Fluconazole                                           NR                      Cure                          12

  58/Nayeri F           5-flucytosine + amphotericin B\                       RA                      Cure                          22
                        5-flucytosine + itraconazole                                                                                

  20/Hennesy MJ         Amphotericin B\                                       TEA                     Cure                          24
                        5-flucytosine                                                                                               

  21/Cardinal E         Amphotericin B                                        RA                      Cure\                         NR
                                                                                                      Dead (UD)                     

  21/Cardinal E         Amphotericin B                                        RA                      Cure\                         12
                                                                                                      Dead (UD)                     

  21/Cardinal E         Fluconazole                                           RA                      Cure                          6

  22/White A            Fluconazole\                                          RA                      Cure                          24
                        Amnphotericin B\                                                                                            
                        Itraconazole                                                                                                

  23/Tunkel AR          Amphotericin B\                                       RA                      Amputation                    NR
                        Ketoconazole\                                                                                               
                        Fluconazole                                                                                                 

  41/Paul J             Amphotericin B + 5-fluorocytosine\                    RA\                     Cure                          24
                        Ketoconazole                                          Arthrodesis                                           

  24/Evans RP           Amphotericin B                                        TEA                     Cure                          24

  24/Evans RP           Amphotericin B                                        TEA                     *S. aureus* infection\        60
                                                                                                      Cure                          

  25/Darouiche RO       Amphotericin B                                        RA                      Cure                          8

  25/Darouiche RO       Amphotericin B                                        RA                      Cure                          1.5

  25/Darouiche RO       Amphotericin B\                                       RA\                     Cure                          36
                        Ketoconazole                                          Arthrodesis                                           

  25/Darouiche RO       Amphotericin B                                        RA                      Cure                          5

  26/Lambertus M        Amphotericin B                                        RA                      *S. epidermidis* infection\   24
                                                                                                      Cure                          

  26 /Lambertus M       Amphotericin B\                                       RA\                     Cure                          14
                        Ketoconazole                                          Arthrodesis                                           

  27/Levine M           Amphotericin B                                        RA\                     Cure                          24
                                                                              Arthrodesis                                           

  28/Iskander MK        Amphotericin B\                                       RA\                     Cure                          NR
                        Ketoconazole                                          Arthrodesis                                           

  29/Koch AE            Amphotericin B\                                       RA\                     Cure                          21
                        5-flucytosine\                                        Arthrodesis                                           
                        Ketoconazole                                                                                                

  30/Lim EVA            Amphotericin B                                        RA                      Cure                          28

  31/Younkin S          5-fluocytosine + amphotericin B                       TEA                     Cure                          24

  32/Lichtman EA        Amphotericin B\                                       RA                      Cure                          3
                        Ketoconazole                                                                                                

  33/Goodman JS         Amphotericin B                                        RA                      Cure                          NR

  33/Goodman JS         Amphotericin B                                        TEA\                    Cure                          12
                                                                              RA\                                                   
                                                                              Arthrodesis                                           

  10/MacGregor RR       Amphotericin B + 5-flucytosine                        RA                      Cure                          12

  45/Jenny JY           Caspofungine + 5-flucytosine\                         OEA                     Cure                          24
                        Voriconazole + 5-flucytosine                                                                                

  45/Jenny JY           Voriconazole + 5-flucytosine\                         OEA                     Cure                          36
                        Fluconazole + 5-flucytosine                                                                                 

  9/Cobo F              Caspofungin\                                          No surgical treatment   Cure                          6
                        Fluconazole                                                                                                 

  PR/Cobo F             Caspofungin 14 days\                                  No surgical treatment   No relapse                    3
                        Fluconazole (expected 6 months)                                                                             
  ---------------------------------------------------------------------------------------------------------------------------------------

**UD:** unrelated disease; **NR:** not reported; **PR:**present report; **TEA:** two-stage exchange arthroplasty; **RA:** Resection arthroplasty; **OEA:** one-stage exchange arthroplasty

**ICS:** impregnated cement spacer; **IB:** impregnated beads
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